VOMITING IS A POTENTIAL ADVERSE DRUG REACTION FOR LEVOMILNACIPRAN. (2017). International Journal of Pharmaceutical Sciences and Drug Research, 9(5), 224-227. https://doi.org/10.25004/IJPSDR.2017.090504